A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety

Abstract

Aims: To investigate if vaginal application of dequalinium chloride (DQC, Fluomizin®) is as effective as vaginal clindamycin (CLM) in the treatment of bacterial vaginosis (BV). Methods: This was a multinational, multicenter, single-blind, randomized trial in 15 centers, including 321 women. They were randomized to either vaginal DQC tablets or vaginal CLM cream. Follow-up visits were 1 week and 1 month after treatment. Clinical cure based on Amsel’s criteria was the primary outcome. Secondary outcomes were rate of treatment failures and recurrences, incidence of post-treatment vulvovaginal candidosis (VVC), lactobacillary grade (LBG), total symptom score (TSC), and safety. Results: Cure rates with DQC (C1: 81.5%, C2: 79.5%) were as high as with CLM (C1: 78.4%, C2: 77.6%). Thus, the treatment with DQC had equal efficacy as CLM cream. A trend to less common post-treatment VVC in the DQC-treated women was observed (DQC: 2.5%, CLM: 7.7%; p = 0.06). Both treatments were well tolerated with no serious adverse events occurring. Conclusion: Vaginal DQC has been shown to be equally effective as CLM cream, to be well tolerated with no systemic safety concerns, and is therefore a valid alternative therapy for women with BV [ClinicalTrials.gov, Med380104, NCT01125410].

Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1

“…Briefly, the Prestwick library of FDA-approved compounds (∼2,000) at a concentration of ∼10 μM was screened against the yeast strain WT[Su9-URA3]. The strain was aliquotted into 384-well pates consisting of 24 columns followed by compound addition with robotic pinning into the assay wells (column [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] in minimal glucose media lacking uracil. For a negative control of cell growth, column 2 contained the WT[Su9-URA3] strain with 1% DMSO.…”

“…1A). DECA has been approved as an antibacterial treatment for oral and vaginal applications (18). Moreover, DECA is used as a "nano-particle" to deliver cargo to the mitochondria (19,20).…”

Management of Abnormal Vaginal Flora as a Risk Factor for Preterm Birth

“…In in vitro fertilization procedures, a relation was found between BV and implantation failures (Ralph et al, 1999), but this relation was not confirmed in another observation (Liversedge et al, 1999). Furthermore, amongst these patients a clear relation of BV with tubal infertility was present, (Liversedge et al, 1999;Wilson et al, 2002) indicating indirectly BV is a risk factor for ascending infection and tubal damage. Interestingly, in one study, not BV, but decreased lactobacilli (AVF) was found to be the risk factor of implantation failure at IVF (Eckert et al, 2003).…”

New strategies for local treatment of vaginal infections

“…Some of these compounds, such as dequalinium chloride, nifuratel and chlorhexidine have been tested in clinical trials for effectiveness compared to traditional therapies, showing positive results [114,135,187] .…”